- Home
- GNLN vs SNGX Comparison
GNLN vs SNGX Comparison
Compare GNLN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLN
- SNGX
- Stock Information
- Founded
- GNLN 2005
- SNGX 1987
- Country
- GNLN United States
- SNGX United States
- Employees
- GNLN N/A
- SNGX N/A
- Industry
- GNLN Durable Goods
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GNLN Consumer Discretionary
- SNGX Health Care
- Exchange
- GNLN Nasdaq
- SNGX Nasdaq
- Market Cap
- GNLN 5.8M
- SNGX 6.5M
- IPO Year
- GNLN 2019
- SNGX 1987
- Fundamental
- Price
- GNLN $0.01
- SNGX $1.93
- Analyst Decision
- GNLN
- SNGX
- Analyst Count
- GNLN 0
- SNGX 0
- Target Price
- GNLN N/A
- SNGX N/A
- AVG Volume (30 Days)
- GNLN 290.1M
- SNGX 18.1K
- Earning Date
- GNLN 05-15-2025
- SNGX 05-09-2025
- Dividend Yield
- GNLN N/A
- SNGX N/A
- EPS Growth
- GNLN N/A
- SNGX N/A
- EPS
- GNLN N/A
- SNGX N/A
- Revenue
- GNLN $9,818,000.00
- SNGX $2,342.00
- Revenue This Year
- GNLN $1,541.21
- SNGX N/A
- Revenue Next Year
- GNLN N/A
- SNGX N/A
- P/E Ratio
- GNLN N/A
- SNGX N/A
- Revenue Growth
- GNLN N/A
- SNGX N/A
- 52 Week Low
- GNLN $0.01
- SNGX $1.68
- 52 Week High
- GNLN $21.80
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- GNLN 20.26
- SNGX 49.95
- Support Level
- GNLN $0.01
- SNGX $1.86
- Resistance Level
- GNLN $0.01
- SNGX $1.97
- Average True Range (ATR)
- GNLN 0.00
- SNGX 0.09
- MACD
- GNLN 0.01
- SNGX 0.01
- Stochastic Oscillator
- GNLN 20.00
- SNGX 70.59
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).